In a significant move to advance oncology research, Carta Healthcare has announced the acquisition of Realyze Intelligence, a company known for its innovative AI technology in clinical trial matching. This acquisition promises to enhance the capabilities of Carta Healthcare’s AI-powered platform, speeding up patient matching to trials and reducing operational costs, thereby setting a new standard in the realm of medical research.
Carta Healthcare Acquires Realyze Intelligence
Carta Healthcare, a leader in transforming clinical data into actionable insights, has recently expanded its technological arsenal by acquiring Realyze Intelligence, a UPMC Enterprises company. This addition equips Carta with advanced tools to optimize clinical trial matching using AI-driven analytics, which processes vast amounts of data rapidly to find ideal patient matches for oncology trials. The integration of Realyze Intelligence into Carta’s suite marks a noteworthy advancement in the use of AI within healthcare.
Enhancing Oncology Trials with AI Technology
Realyze Intelligence specializes in the rapid analysis of both structured and unstructured electronic health record (EHR) data to identify potential trial participants. Their clinician-trained AI technology is capable of assembling patient cohorts in just seconds—a process that normally takes hours or days when performed manually. This technology is not only fast but also precise, ensuring that the most suitable candidates are matched to the appropriate clinical studies. Through the acquisition, Carta Healthcare aims to integrate these capabilities widely across its operations, thus promising faster and more cost-effective clinical trials.
Benefits and Outcomes of the Acquisition
The acquisition of Realyze Intelligence by Carta Healthcare is set to deliver substantial benefits. For instance, previous analyses showed that use of Realyze Intelligence’s software at UPMC Hillman Cancer Center resulted in a sevenfold increase in patient matches to trials and doubled the enrollment rates as compared to periods without the software. Such improvements underscore the enhanced efficiency and effectiveness that AI integration brings to clinical trials. More broadly, the acquisition will enable higher participation rates in trials, improved patient outcomes, and optimized research timelines and costs.
In conclusion, the acquisition of Realyze Intelligence by Carta Healthcare marks a pivotal development in the enhancement of clinical trials through AI technology. By streamlining the patient matching process and reducing the timeline and costs associated with data processing, Carta is poised to lead in the innovation of healthcare services. This collaboration not only accelerates cancer research but also improves the lives of patients by speeding their access to the latest therapies.
Don’t miss our latest Startup News: TECNO Image Matrix Transforms Smartphone Photography
